This study provided for the first time a value set for calculating quality-adjusted life years from the EQ-5D instrument in Iran. The mean values for the 42 health states ranged from 0.934 for state 11121 to -0.142 for state 33333. The final model yielded the best fit for the time trade-off value at the individual level with an overall R2 of 0.45 and a mean absolute error of 0.214. The analysis was performed for 846 respondents. Generalized least squares regression with random effect was used to predict values for health states. Each respondent valued 11 health states using the time trade-off method. Forty-two health states were selected and valued from the 243 states derived from the EQ-5D-3L instrument. The participants were selected by a stratified random sampling method and were interviewed face-to-face at their usual residence. To estimate a preference valuation set for EQ-5D 3-level (3L) health states from the perspective of the general population in the capital of Iran.Įight hundred seventy adults aged ≥18 years were interviewed in Tehran (Iran's capital) from July to November 2013. The EuroQol 5-dimension (EQ-5D) is a standard instrument that is widely used for measuring health-related quality of life and quality-adjusted life years in economic evaluation of healthcare interventions. The study results revealed that FVIII prepared using blood plasma for hemophilia A patients had higher cost-effectiveness compared with that made using recombinant technique. Moreover, the results of one-way (univariate) sensitivity analysis demonstrated the highest sensitivity to the utility in patients who had been injected with blood-plasma-derived FVIII and had been successfully treated.Conclusion Since the incremental cost-effectiveness ratio (ICER) for the recombinant medications was over three times of the threshold level, it was considered as overwhelming because of its high cost in spite of its better effectiveness. #IFACTOR DIET PROGRAM COST PRO#The information was ultimately analyzed using the TreeAge Pro 2011 and the Microsoft Office Excel 2010 software.ResultsThe results revealed that the recombinant diet therapy had higher costs and effectiveness compared with blood-plasma-derived FVIII, so that the mean costs of these two diet therapies were equal to 37,624 and 20,349 purchasing power parity (PPP) $ with utility scores of 0.78 and 0.62 respectively. Besides, one-way (univariate) sensitivity analysis was performed to quantify uncertainty effects of the study parameters. Quality-adjusted life year (QALY) was subsequently determined as the measure of effectiveness (MOE). Moreover, costs were reviewed from societal perspective. The decision tree structure was also utilized to estimate economic and clinical outcomes. To this end, a total number of 120 patients were randomly selected using Krejcie & Morgan’s Table and then received blood plasma and recombinant FVIII. This study was an economic evaluation fulfilled through a cost-utility approach. Thus, the present study aimed to analyze cost-utility of two FVIII diet therapies prepared using blood plasma and recombinant technique.Methods Hemophilia is known as one of the most common coagulation disorders whose treatment costs are particularly high in developing countries, and about 90% of them are related to factor VIII (FVIII) and direct medical costs (DMCs).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |